The PSAPL1 activators encompass a set of chemicals that either directly or indirectly modulate the activity of PSAPL1, a protein associated with prosaposin and instrumental in lysosomal sphingolipid degradation. Since PSAPL1's role revolves around sphingolipid degradation, chemicals that influence sphingolipid metabolism often intersect with the functional landscape of PSAPL1. Fenretinide, for instance, is an inducer of ceramide synthesis, a primary component of sphingolipids. An upregulation in ceramide synthesis exerts a demand on lysosomal degradation pathways, which PSAPL1 may be a part of, ensuring cellular homeostasis of sphingolipids. Fingolimod, another chemical in this class, is a modulator of sphingosine 1-phosphate receptors. By affecting such sphingolipid signaling mechanisms, it casts an indirect effect on the lysosomal degradation infrastructure of the cell, wherein PSAPL1 may be a significant player.
Continuing on this theme, the chemical Myriocin inhibits a pivotal enzyme in sphingolipid biosynthesis, serine palmitoyltransferase. Any alteration in sphingolipid synthesis, such as that induced by Myriocin, can indirectly elicit a response from lysosomal degradation systems, in which PSAPL1 is hypothesized to function. Similarly, chemicals like Desipramine, which inhibits acid sphingomyelinase, lead to sphingomyelin accumulation, creating a cascade effect that could influence pathways where PSAPL1 operates. With its function intricately tied to sphingolipid dynamics, PSAPL1's activity becomes particularly responsive to chemicals like Miglustat and PDMP, which modulate glucosylceramide synthase activity. This underscores the interplay between sphingolipid synthesis, degradation, and the modulation of PSAPL1's role in these processes by various chemicals.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
An inducer of ceramide synthesis. As ceramides are a type of sphingolipid, upregulation of their synthesis can necessitate enhanced lysosomal degradation, possibly involving PSAPL1. | ||||||
Fingolimod | 162359-55-9 | sc-507334 | 10 mg | $160.00 | ||
A sphingosine 1-phosphate receptor modulator. By affecting sphingolipid signaling, it can indirectly demand more from lysosomal degradation pathways where PSAPL1 might be involved. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $88.00 $190.00 $500.00 $2400.00 $9200.00 $15000.00 | 2 | |
A backbone of sphingolipid metabolism. Its increase might indirectly stimulate lysosomal degradation processes involving PSAPL1 to maintain homeostasis. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | $65.00 $115.00 | 6 | |
Inhibits acid sphingomyelinase, leading to accumulation of sphingomyelin. This can stimulate lysosomal degradation pathways, indirectly affecting PSAPL1. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $106.00 | 8 | |
Inhibitor of serine palmitoyltransferase, a key enzyme in sphingolipid biosynthesis. Alterations in sphingolipid levels can indirectly modulate lysosomal degradation processes involving PSAPL1. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Influences sphingolipid metabolism, especially ceramides. Modulating sphingolipid levels can have indirect effects on lysosomal degradation processes where PSAPL1 participates. | ||||||
SEW2871 | 256414-75-2 | sc-203251 sc-203251A | 5 mg 10 mg | $37.00 $52.00 | 1 | |
By being a selective agonist of sphingosine-1-phosphate 1 (S1P1) receptors, it modulates sphingolipid signaling which can indirectly affect lysosomal degradation pathways involving PSAPL1. | ||||||
C2 Ceramide | 3102-57-6 | sc-201375 sc-201375A | 5 mg 25 mg | $77.00 $316.00 | 12 | |
A cell-permeable ceramide analog. Its introduction can stimulate lysosomal degradation mechanisms to maintain sphingolipid balance, potentially involving PSAPL1. | ||||||
Matrine | 519-02-8 | sc-205741 sc-205741A | 100 mg 500 mg | $242.00 $544.00 | ||
Impacts sphingolipid metabolism, especially ceramide pathways. Its modulation of sphingolipid dynamics can indirectly stimulate PSAPL1-associated lysosomal degradation processes. | ||||||